Clinical Trials Browser

Phase 1/2 × toripalimab × Head & Neck × Clear all

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Non-Small-Cell Lung, Melanoma, Endometrial Neoplasms

NCT07258979 2025-12-02

A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.

Phase 1/2 Recruiting

202 enrolled

Head & Neck

Nasopharyngeal Carcinoma, Recurrence

NCT05955105 2024-05-21

A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies

Phase 1/2 Recruiting

200 enrolled

BreastDermatologicGynecologicHead & NeckSarcomaThoracic

Nasopharyngeal Carcinoma, Carcinoma, Non-Small-Cell Lung, Uterine Cervical Neoplasms, Head and Neck Neoplasms, Melanoma, Ovarian Neoplasms, Sarcoma, Endometrial Neoplasms, Triple Negative Breast Neoplasms

NCT04856631 2022-12-19

A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer

Phase 1/2 Unknown

88 enrolled

Head & Neck

Head and Neck Squamous Cell Cancer

NCT05341193 2022-04-22

PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma

Phase 1/2 Unknown

32 enrolled

Head & Neck

Nasopharyngeal Carcinoma

NCT02915432 2021-12-13

The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC

Phase 1/2 Unknown

401 enrolled 1 FDA

GastrointestinalHead & Neck

Squamous Cell Carcinoma of Head and Neck, Nasopharyngeal Carcinoma, Esophageal Squamous Cell Carcinoma

Clinical Trials

STC-15 as a Part of Combination Therapy With Toripalimab in Selected Advanced Cancers

A Study of YL201 in Combination With Toripalimab and With or Without Cisplatin in Nasopharyngeal Carcinoma.

A Study of ILB2109 and Toripalimab in Patients With Advanced Solid Malignancies

A Study of Toripalimab Injection (JS001) + Cetuximab in Treatment of Advanced Head and Neck Squamous Cell Cancer

PD-1 Blockade and Bevacizumab Replace Cisplatin in Locoregionally Advanced Nasopharyngeal Carcinoma

The Study to Evaluate Toripalimab (JS001) in Patients With Advanced GC, ESCC, NPC, HNSCC